Wei K. Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wei K. Zhao has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Theodore Robert Levin
Kaiser Permanente Division of Research, Pleasanton, California, USA
7 shared publications - Chyke A. Doubeni
The Ohio State University Wexner Medical Center, 410 West Tenth Avenue, Columbus, OH 43210, USA
6 shared publications - Douglas A. Corley
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
6 shared publications Joanne E. Schottinger
6 shared publications- Ann G. Zauber
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY
5 shared publications Christopher Jensen
4 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
99 - Potentially Modifiable Factors in the Screening Process to Prevent Death from Colorectal Cancer
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
99 - Potentially Modifiable Factors in the Screening Process to Prevent Death from Colorectal Cancer
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S177-S178
Long-Term Impact of Colorectal Cancer Screening Using a Combination of Fecal Immunochemical Testing and Lower Bowel Endoscopy in a Large, Community-Based Integrated Healthcare Setting
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S177-S178
Long-Term Impact of Colorectal Cancer Screening Using a Combination of Fecal Immunochemical Testing and Lower Bowel Endoscopy in a Large, Community-Based Integrated Healthcare Setting
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S536-S537
Repeat Annual Fecal Immunochemical Testing Patterns in a Large Community-Based Integrated Healthcare Setting
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S536-S537
Repeat Annual Fecal Immunochemical Testing Patterns in a Large Community-Based Integrated Healthcare Setting
- 2 January 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (3) , 678-688
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue
Background Fecal immunochemical test (FIT) screening detects most asymptomatic colorectal cancers. Combining FIT screening with stool-based genetic biomarkers increases sensitivity for cancer, but whether DNA biomarkers (biomarkers) differ for cancers detected versus missed by FIT screening has not been evaluated in a community-based population. Aims To evaluate tissue biomarkers among Kaiser Permanente Northern California patients diagnosed with colorectal cancer within 2 years after FIT screening. Methods FIT-negative and FIT-positive colorectal cancer patients 50–77 years of age were matched on age, sex, and cancer stage. Adequate DNA was isolated from paraffin-embedded specimens in 210 FIT-negative and 211 FIT-positive patients. Quantitative allele-specific real-time target and signal amplification assays were performed for 7 K-ras mutations and 10 aberrantly methylated DNA biomarkers (NDRG4, BMP3, SFMBT2_895, SFMBT2_896, SFMBT2_897, CHST2_7890, PDGFD, VAV3, DTX1, CHST2_7889). Results One or more biomarkers were found in 414 of 421 CRCs (98.3%). Biomarker expression was not associated with FIT status, with the exception of higher SFMBT2_897 expression in FIT-negative (194 of 210; 92.4%) than in FIT-positive cancers (180 of 211; 85.3%; p = 0.02). There were no consistent differences in biomarker expression by FIT status within age, sex, stage, and cancer location subgroups. Conclusions The biomarkers of a currently in-use multi-target stool DNA test (K-ras, NDRG4, and BMP3) and eight newly characterized methylated biomarkers were commonly expressed in tumor tissue specimens, independent of FIT result. Additional study using stool-based testing with these new biomarkers will allow assessment of sensitivity, specificity, and clinical utility.
- 2 January 2017
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (3) , 678-688
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue
Background Fecal immunochemical test (FIT) screening detects most asymptomatic colorectal cancers. Combining FIT screening with stool-based genetic biomarkers increases sensitivity for cancer, but whether DNA biomarkers (biomarkers) differ for cancers detected versus missed by FIT screening has not been evaluated in a community-based population. Aims To evaluate tissue biomarkers among Kaiser Permanente Northern California patients diagnosed with colorectal cancer within 2 years after FIT screening. Methods FIT-negative and FIT-positive colorectal cancer patients 50–77 years of age were matched on age, sex, and cancer stage. Adequate DNA was isolated from paraffin-embedded specimens in 210 FIT-negative and 211 FIT-positive patients. Quantitative allele-specific real-time target and signal amplification assays were performed for 7 K-ras mutations and 10 aberrantly methylated DNA biomarkers (NDRG4, BMP3, SFMBT2_895, SFMBT2_896, SFMBT2_897, CHST2_7890, PDGFD, VAV3, DTX1, CHST2_7889). Results One or more biomarkers were found in 414 of 421 CRCs (98.3%). Biomarker expression was not associated with FIT status, with the exception of higher SFMBT2_897 expression in FIT-negative (194 of 210; 92.4%) than in FIT-positive cancers (180 of 211; 85.3%; p = 0.02). There were no consistent differences in biomarker expression by FIT status within age, sex, stage, and cancer location subgroups. Conclusions The biomarkers of a currently in-use multi-target stool DNA test (K-ras, NDRG4, and BMP3) and eight newly characterized methylated biomarkers were commonly expressed in tumor tissue specimens, independent of FIT result. Additional study using stool-based testing with these new biomarkers will allow assessment of sensitivity, specificity, and clinical utility.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S45
175 Colonoscopy Delay After a Positive Fecal Test and Risk of Colorectal Cancer-Related Outcomes
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S45
175 Colonoscopy Delay After a Positive Fecal Test and Risk of Colorectal Cancer-Related Outcomes
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S852-S853
Tu1132 Cancer Incidence and Mortality Risks in a Large United States Barrett's Esophagus Cohort
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S852-S853
Tu1132 Cancer Incidence and Mortality Risks in a Large United States Barrett's Esophagus Cohort
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S61
251 Screening Colonoscopy and the Risk of Death From Right and Left Colon Cancers
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S61
251 Screening Colonoscopy and the Risk of Death From Right and Left Colon Cancers
- 12 September 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (2) , 436-443
Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s Esophagus
Background The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of esophageal adenocarcinoma; however, it is unknown where these agents may act in the proposed pathway from normal mucosa to Barrett’s esophagus to esophageal adenocarcinoma. Aim The aim of the study was to evaluate the association between aspirin and NSAID use and Barrett’s esophagus in a case–control study within a large community-based population. Methods We conducted a case–control study of aspirin/NSAID use and Barrett’s esophagus within the Kaiser Permanente Northern California population. Cases had a new diagnosis of Barrett’s esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett’s esophagus. Results Persons with Barrett’s esophagus were less likely to use aspirin than population controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39–0.87]; a stronger association was found among cases and controls with reflux symptoms (OR 0.49, 95 % CI 0.32–0.75; p value interaction = 0.004). Similar associations were found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 0.35–0.81), although NSAID use alone was not significantly associated with Barrett’s esophagus (OR 0.74, 95 % CI 0.47–1.16). The strength of the association was highest among persons with at least moderate-to-high total medication intake. Conclusions Regular use of aspirin or NSAIDs was associated with a decreased risk of Barrett’s esophagus, particularly among persons with gastroesophageal reflux disease symptoms. These findings have implications for chemoprevention, as some of the previously described protective association between aspirin/NSAIDs and esophageal adenocarcinoma may be explained by events that occur prior to the development of Barrett’s esophagus.
- 12 September 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (2) , 436-443
Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s Esophagus
Background The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of esophageal adenocarcinoma; however, it is unknown where these agents may act in the proposed pathway from normal mucosa to Barrett’s esophagus to esophageal adenocarcinoma. Aim The aim of the study was to evaluate the association between aspirin and NSAID use and Barrett’s esophagus in a case–control study within a large community-based population. Methods We conducted a case–control study of aspirin/NSAID use and Barrett’s esophagus within the Kaiser Permanente Northern California population. Cases had a new diagnosis of Barrett’s esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett’s esophagus. Results Persons with Barrett’s esophagus were less likely to use aspirin than population controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39–0.87]; a stronger association was found among cases and controls with reflux symptoms (OR 0.49, 95 % CI 0.32–0.75; p value interaction = 0.004). Similar associations were found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 0.35–0.81), although NSAID use alone was not significantly associated with Barrett’s esophagus (OR 0.74, 95 % CI 0.47–1.16). The strength of the association was highest among persons with at least moderate-to-high total medication intake. Conclusions Regular use of aspirin or NSAIDs was associated with a decreased risk of Barrett’s esophagus, particularly among persons with gastroesophageal reflux disease symptoms. These findings have implications for chemoprevention, as some of the previously described protective association between aspirin/NSAIDs and esophageal adenocarcinoma may be explained by events that occur prior to the development of Barrett’s esophagus.